Bionano Genomics (MEX:BNGO) EBIT: MXN-555.4 Mil (TTM As of Mar. 2026)


MEX:BNGO Bionano Genomics Inc MEX:BNGO
61 GF Score
Price MXN19.92
GF Value MXN27.78
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bionano Genomics EBIT?

Bionano Genomics MEX:BNGO +0.61% 61 EBIT is MXN-555.4 Mil as of Mar. 2026. GuruFocus rates MEX:BNGO with a GF Score™ of 61/100 and a GF Value™ of MXN27.78 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Bionano Genomics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN-148.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-555.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bionano Genomics's annualized ROC % for the quarter that ended in Mar. 2026 was -68.90%. Bionano Genomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -110.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bionano Genomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -202.06%.


Bionano Genomics  (MEX:BNGO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bionano Genomics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-569.616 * ( 1 - 0% )/( (852.803 + 800.634)/ 2 )
=-569.616/826.7185
=-68.90 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1324.931 - 125.176 - ( 346.952 - max(0, 413.087 - 817.207+346.952))
=852.803

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1168.591 - 108.196 - ( 259.761 - max(0, 382.798 - 702.824+259.761))
=800.634

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bionano Genomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-592.988/( ( (380.983 + max(73.985, 0)) + (363.287 + max(259.418, 0)) )/ 2 )
=-592.988/( ( 454.968 + 622.705 )/ 2 )
=-592.988/538.8365
=-110.05 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(93.63 + 98.095 + 278.314) - (125.176 + 17.412 + 253.466)
=73.985

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(74.529 + 95.7 + 272.834) - (108.196 + 20.305 + 55.144)
=259.418

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bionano Genomics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-555.4/274.871
=-202.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionano Genomics EBIT Related Terms


Bionano Genomics EBIT Historical Data

* Premium members only.

The historical data trend for Bionano Genomics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics EBIT Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,584.19 -2,542.55 -3,996.25 -2,286.01 -468.69

Bionano Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.58 -116.50 -149.74 -140.91 -148.25

MEX:BNGO vs UEEC, ZJYL, RGNT: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Bionano Genomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionano Genomics EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's EV-to-EBIT falls into.


MEX:BNGO
61GF Score
Bionano Genomics Inc MEX:BNGO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionano Genomics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-555.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN-555.4 Mil mean?
Bionano Genomics (MEX:BNGO) has a EBIT of MXN-555.4 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bionano Genomics.
Is Bionano Genomics' EBIT too high?
Bionano Genomics' current EBIT is MXN-555.4 Mil. Overall, Bionano Genomics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' EBIT compare to UEEC and ZJYL?
Bionano Genomics' EBIT of MXN-555.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bionano Genomics. Bionano Genomics's current EBIT is MXN-555.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN27.78, compared to a current price of MXN19.92 — trading 28.3% below its estimated fair value. The current EBIT is MXN-555.4 Mil. Bionano Genomics' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current EBIT is MXN-555.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?

Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued. The current stock price of MXN19.92 is trading 28.3% below its estimated GF Value™ of MXN27.78. GuruFocus considers Bionano Genomics to be Modestly Undervalued.

Key valuation signals for MEX:BNGO:

  • EBIT: MXN-555.4 Mil
  • GF Value™: MXN27.78 vs. price of MXN19.92 (28.3% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bionano Genomics Business Description

Other Exchanges BNGO:USA
Address 9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
61GF Score

Get the complete analysis for MEX:BNGO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN19.92
Price
MXN27.78
GF Value